Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer
Serena Di Cosimo(Fondazione IRCCS Istituto Nazionale dei Tumori), Francesco Cognetti(Apple (Israel)), Paolo Carlini(National Cancer Institute), Alessandra Fabi(Agostino Gemelli University Polyclinic), Enzo Maria Ruggeri, Michele Stanislaw Milella(University of Verona), G. Ferretti(Istituti di Ricovero e Cura a Carattere Scientifico), Isabella Sperduti(San Gallicano Hospital), Andrea Alimonti(Veneto Institute of Molecular Medicine), Alain Gelibter(Policlinico Umberto I), Paola Papaldo(Cancer Institute (WIA)), Diana Giannarelli(Agostino Gemelli University Polyclinic), Mariangela Ciccarese, Mario Mandalà(University of Perugia)
Cited by 64
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k